<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/04/shutterstock_2518383895-430x241.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/04/shutterstock_2518383895-430x241.jpg"/></p>
<p>Terremoto 现在将推进其下一代 AKT 抑制剂在肿瘤学和罕见疾病领域的项目。图片来源：Andrii Yalanskyi / Shutterstock.com。</p>
<p>Terremoto Biosciences 已完成一轮价值 1.08 亿美元的 C 轮融资，这将使公司能够推动其一系列 AKT-1 选择性抑制剂在多个罕见疾病和癌症中的早期临床开发。</p>
<p>这家位于加利福尼亚的生物科技公司从多个新老投资者那里获得了这笔资金，包括诺和诺德控股、OrbiMed 和 Third Rock Ventures 等行业巨头，以及 RA Capital Management、Cormorant Asset Management 和 BeOne Medicines。</p>
<h3>深入了解 GlobalData</h3>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>报告</p>
<h4>制药中的免疫肿瘤学：癌症嵌合抗原受体...</h4>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>报告</p>
<h4>制药中的免疫肿瘤学：癌症放射治疗</h4>
<h5>深入了解 GlobalData</h5>
<p>商业智能的黄金标准。</p>
<p>了解更多</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>发现高效的 B2B 营销</h4>
<p>结合商业智能和编辑卓越，覆盖 36 个领先媒体平台的专业人士。</p>
<p>了解更多</p>
<p>有了这笔资金，Terremoto 现在将推进其 AKT-1 选择性抑制剂进入 I 期临床试验，特别关注激素受体（HR）阳性乳腺癌以及罕见出血性疾病，如 遗传性出血性毛细血管扩张症 (HHT)。</p>
<p>Terremoto 在肿瘤学领域的明星资产是其选择性 ATK1 阻断剂 TER-2031，该公司目前正在进行首个人体 I 期临床试验（NCT07109726）。该研究正在探索该药物在携带 PIK3CA、AKT 或 PTEN 突变的实体肿瘤中的安全性和有效性，涉及乳腺癌、卵巢癌、鳞状细胞头颈癌和子宫内膜癌等适应症，具体信息可参见 ClinicalTrials.gov。</p>
<p>除了在肿瘤学方面的努力，Terremoto 希望在 2026 年晚些时候将另一种 ATK1 抑制剂 TER-4480 推向 HHT 临床。根据 Cure HHT 的数据，监管机构尚未批准任何治疗这种遗传性出血性疾病的疗法，该疾病影响全球约 140 万人，使其成为美国仅次于冯·威尔布兰病的第二常见出血性疾病。</p>
<h2>使 AKTs 更加耐受</h2>
<p>2023 年 11 月，阿斯利康取得了里程碑，成为第一家获得 AKT 抑制剂批准的公司，Truqap (capivasertib) 现已可供 HR 阳性、HER2 阴性晚期乳腺癌患者使用。</p>
<p>尽管非选择性 AKT1、2 和 3 阻断剂在多种实体肿瘤适应症中显示出潜力，并已成为阿斯利康的旗舰肿瘤产品之一，但它可能会导致显著的副作用。在治疗过程中，一些患者会出现葡萄糖失调，以及对感染和肝毒性的易感性增加。</p>
<p>根据 Terremoto 的说法，与 AKT 抑制剂相关的副作用通常与 AKT2 有关。这使得公司推测，选择性 AKT1 疗法可以克服与该药物类别相关的毒性障碍，为患者提供更耐受的治疗。</p>
<p>Terremoto 并不是唯一一家试图利用下一代 AKT 方法的生物科技公司，Atavistik Bio 最近在其选择性别构 AKT1 E17K 阻断剂 ATV-1601 的 I 期临床试验中 给第一位受试者用药，该试验针对的是患有实体肿瘤的成年人。</p>
<p>根据 GlobalData 的制药智能中心，目前有 37 项正在进行的临床试验在评估 AKT 抑制剂的 I-III 期。</p>
<p>GlobalData 是 <em>Pharmaceutical Technology</em> 的母公司。</p>

TBIO

纽交所高增长板生物技术指数 ETF - First Trust

<p>Terremoto Biosciences 在一轮 C 轮融资中筹集了 1.08 亿美元，以推进其针对癌症和罕见疾病的 AKT-1 选择性抑制剂。此次融资来自包括 Novo Holdings 和 OrbiMed 在内的投资者，将支持早期临床开发，重点关注激素受体阳性乳腺癌和遗传性出血性毛细血管扩张症（HHT）。Terremoto 的主要资产 TER-2031 目前正在进行针对特定突变的实体瘤的 I 期临床试验。该公司旨在提供一种比现有 AKT 抑制剂更耐受的治疗选择，因为后者可能会导致显著的副作用</p>

<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/04/shutterstock_2518383895-430x241.jpg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/04/shutterstock_2518383895-430x241.jpg"/></p>
<p>Terremoto will now progress its next-generation AKT inhibitor programmes in oncology and rare disease. Credit: Andrii Yalanskyi / Shutterstock.com.</p>
<div class="lb-trans"><p>Terremoto 现在将推进其下一代 AKT 抑制剂在肿瘤学和罕见疾病领域的项目。图片来源：Andrii Yalanskyi / Shutterstock.com。</p>
</div><p>Terremoto Biosciences has closed a Series C financing round worth $108m, which will allow the company to usher its range of AKT-1 selective inhibitors through early clinical development across multiple rare diseases and cancer.</p>
<div class="lb-trans"><p>Terremoto Biosciences 已完成一轮价值 1.08 亿美元的 C 轮融资，这将使公司能够推动其一系列 AKT-1 选择性抑制剂在多个罕见疾病和癌症中的早期临床开发。</p>
</div><p>The California-based biotech secured this funding from several new and existing investors, including industry giants like Novo Holdings, OrbiMed and Third Rock Ventures, as well as RA Capital Management, Cormorant Asset Management and BeOne Medicines.</p>
<div class="lb-trans"><p>这家位于加利福尼亚的生物科技公司从多个新老投资者那里获得了这笔资金，包括诺和诺德控股、OrbiMed 和 Third Rock Ventures 等行业巨头，以及 RA Capital Management、Cormorant Asset Management 和 BeOne Medicines。</p>
</div><h3>Go deeper with GlobalData</h3>
<div class="lb-trans"><h3>深入了解 GlobalData</h3>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>报告</p>
</div><h4>Immuno-oncology in Pharmaceuticals: Cancer chimeric antigen recepto...</h4>
<div class="lb-trans"><h4>制药中的免疫肿瘤学：癌症嵌合抗原受体...</h4>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>报告</p>
</div><h4>Immuno-oncology in Pharmaceuticals: Cancer radiotherapy</h4>
<div class="lb-trans"><h4>制药中的免疫肿瘤学：癌症放射治疗</h4>
</div><h5>Go deeper with GlobalData</h5>
<div class="lb-trans"><h5>深入了解 GlobalData</h5>
</div><p>The gold standard of business intelligence.</p>
<div class="lb-trans"><p>商业智能的黄金标准。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>了解更多</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>Discover B2B Marketing That Performs</h4>
<div class="lb-trans"><h4>发现高效的 B2B 营销</h4>
</div><p>Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.</p>
<div class="lb-trans"><p>结合商业智能和编辑卓越，覆盖 36 个领先媒体平台的专业人士。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>了解更多</p>
</div><p>With this cash in hand, Terremoto will now advance its AKT-1-selective inhibitors through Phase I, with a specific focus on oncological indications like hormone receptor (HR)-positive breast cancer, as well as rare bleeding disorders, hereditary haemorrhagic telangiectasia (HHT).</p>
<div class="lb-trans"><p>有了这笔资金，Terremoto 现在将推进其 AKT-1 选择性抑制剂进入 I 期临床试验，特别关注激素受体（HR）阳性乳腺癌以及罕见出血性疾病，如 遗传性出血性毛细血管扩张症 (HHT)。</p>
</div><p>The jewel in Terremoto’s oncology crown and its most developed asset is its selective ATK1 blocker, TER-2031, which the company is currently evaluating in a first-in-human Phase I trial (NCT07109726). This study is exploring the drug’s safety and efficacy in solid tumours harbouring PIK3CA, AKT, or PTEN mutations – incorporating patients with indications like breast, ovarian, squamous head and neck and endometrial cancer, as per ClinicalTrials.gov.</p>
<div class="lb-trans"><p>Terremoto 在肿瘤学领域的明星资产是其选择性 ATK1 阻断剂 TER-2031，该公司目前正在进行首个人体 I 期临床试验（NCT07109726）。该研究正在探索该药物在携带 PIK3CA、AKT 或 PTEN 突变的实体肿瘤中的安全性和有效性，涉及乳腺癌、卵巢癌、鳞状细胞头颈癌和子宫内膜癌等适应症，具体信息可参见 ClinicalTrials.gov。</p>
</div><p>Alongside its efforts in oncology, Terremoto hopes to take TER-4480, another ATK1 inhibitor, to the clinic in HHT later in 2026. Regulators are yet to approve any therapies for this inherited bleeding disorder, which impacts around 1.4 million people worldwide, as per Cure HHT. This makes it the second most common bleeding disorder in the US after Von Willebrand disease.</p>
<div class="lb-trans"><p>除了在肿瘤学方面的努力，Terremoto 希望在 2026 年晚些时候将另一种 ATK1 抑制剂 TER-4480 推向 HHT 临床。根据 Cure HHT 的数据，监管机构尚未批准任何治疗这种遗传性出血性疾病的疗法，该疾病影响全球约 140 万人，使其成为美国仅次于冯·威尔布兰病的第二常见出血性疾病。</p>
</div><h2>Making AKTs more tolerable</h2>
<div class="lb-trans"><h2>使 AKTs 更加耐受</h2>
</div><p>In November 2023, AstraZeneca notched a milestone by becoming the first company to secure approval for an AKT inhibitor, Truqap (capivasertib), which is now available to patients with HR-positive, HER2-negative advanced breast cancer.</p>
<div class="lb-trans"><p>2023 年 11 月，阿斯利康取得了里程碑，成为第一家获得 AKT 抑制剂批准的公司，Truqap (capivasertib) 现已可供 HR 阳性、HER2 阴性晚期乳腺癌患者使用。</p>
</div><p>While the non-selective AKT1, 2 and 3 blocker has demonstrated its potential in multiple solid tumour indications and has become one of AstraZeneca’s flagship oncology products, it can cause significant side effects. Upon treatment, some patients experience glucose dysregulation, as well as increased susceptibility to infections and liver toxicity.</p>
<div class="lb-trans"><p>尽管非选择性 AKT1、2 和 3 阻断剂在多种实体肿瘤适应症中显示出潜力，并已成为阿斯利康的旗舰肿瘤产品之一，但它可能会导致显著的副作用。在治疗过程中，一些患者会出现葡萄糖失调，以及对感染和肝毒性的易感性增加。</p>
</div><p>According to Terremoto, side effects associated with AKT inhibitors are generally linked to AKT2. This led the company to theorise that an AKT1-selective therapy could overcome the toxicity hurdles associated with this drug class – offering a more tolerable therapy for patients.</p>
<div class="lb-trans"><p>根据 Terremoto 的说法，与 AKT 抑制剂相关的副作用通常与 AKT2 有关。这使得公司推测，选择性 AKT1 疗法可以克服与该药物类别相关的毒性障碍，为患者提供更耐受的治疗。</p>
</div><p>Terremoto is not the only biotech attempting to harness a next-generation AKT approach, as Atavistik Bio recently dosed its first subject in a Phase I trial on its selective allosteric AKT1 E17K blocker, ATV-1601, in adults with solid tumours.</p>
<div class="lb-trans"><p>Terremoto 并不是唯一一家试图利用下一代 AKT 方法的生物科技公司，Atavistik Bio 最近在其选择性别构 AKT1 E17K 阻断剂 ATV-1601 的 I 期临床试验中 给第一位受试者用药，该试验针对的是患有实体肿瘤的成年人。</p>
</div><p>According to GlobalData’s Pharmaceutical Intelligence Center, there are 37 ongoing clinical trials evaluating AKT inhibitors in Phase I-III.</p>
<div class="lb-trans"><p>根据 GlobalData 的制药智能中心，目前有 37 项正在进行的临床试验在评估 AKT 抑制剂的 I-III 期。</p>
</div><p>GlobalData is the parent company of <em>Pharmaceutical Technology</em>.</p>
<div class="lb-trans"><p>GlobalData 是 <em>Pharmaceutical Technology</em> 的母公司。</p>
</div>

Terremoto wins $108m in Series C to drive cancer and rare disease programmes

Pharmaceutical Technology

Telesis Bio

MBX Biosciences

美国医药设备 ETF - iShares

Invesco Nasdaq Biotechnology ETF

基因改革 ETF - ARK

纳斯达克生物科技指数 ETF - iShares Nasdaq

标普生物技术 3 倍做多 - Direxion

标普健康医疗设备 ETF - SPDR

标普全球医疗股指数 ETF - iShares

医疗业 ETF - SPDR

生物科技 ETF - VanEck Vectors

2 倍做多纳斯达克生物技术 ETF - ProShares

标普生物技术 ETF - SPDR

动态生物技术与基因组 ETF - Invesco

医药突破 ETF - ALPS

Terremoto 获得 1.08 亿美元的 C 轮融资，用于推进癌症和罕见疾病项目